Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Practice variation on hospital level in the systemic treatment of metastatic colorectal cancer in The Netherlands: a population-based study

Published:2020-02-12 Issue:4 Volume:59 Page:395-403
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Keikes Lotte¹²,Koopman Miriam³^ORCID,Stuiver Martijn M.⁴,Lemmens Valery E. P. P.²,van Oijen Martijn G. H.¹²,Punt Cornelis J. A.¹

Affiliation:

1. Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;

2. Department of Research, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands;

3. Department of Medical Oncology, University Medical Centre, Utrecht University, Utrecht, The Netherlands;

4. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2020.1722320

Reference31 articles.

1. Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy

2. Overall Survival of Patients With Advanced Colorectal Cancer Correlates With Availability of Fluorouracil, Irinotecan, and Oxaliplatin Regardless of Whether Doublet or Single-Agent Therapy Is Used First Line

3. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial

4. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial

5. Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Improving sustainability of a patient decision aid for systemic treatment of metastatic colorectal cancer: A qualitative study;PEC Innovation;2024-12

2. Triplet chemotherapy with or without bevacizumab as first line treatment for metastatic colorectal cancer: An AGEO multicenter real-world study;Digestive and Liver Disease;2024-09

3. Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?;Current Treatment Options in Oncology;2024-02-17

4. Temporal development in survival, and gender and regional differences in the Swedish population of patients with synchronous and metachronous metastatic colorectal cancer;Acta Oncologica;2022-09-24

5. Predictive value of chromosome 18q11.2‐q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III ‐trial AGITG‐MAX;International Journal of Cancer;2022-05-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3